About the company
22nd Century Group Inc is a pioneering biotechnology company based in the United States, dedicated to revolutionizing health and wellness through the utilization of alkaloid plant technologies. The company has two distinct operating segments, each focused on driving innovative solutions in different fields. The first segment of 22nd Century Group Inc is centered around the transformation of the tobacco industry. Through extensive research and development, the company has successfully developed and commercialized its proprietary Very Low Nicotine Content (VLNC) tobacco plants and cigarette products. These groundbreaking creations contain a staggering 95% less nicotine than traditional tobacco and cigarettes, offering a considerably reduced risk to consumers. Notably, 22nd Century Group Inc also produces research cigarettes which have found widespread use in scientific studies, marketed under the brand name SPECTRUM. This segment contributes significantly to the company's revenue stream and solidifies their position as leaders in the nicotine reduction field. The second segment of the company deals with the burgeoning hemp and cannabis industry. Leveraging their expertise in alkaloid plant technologies, 22nd Century Group Inc provides hemp-derived cannabinoid ingredients and active pharmaceutical ingredients (API). These offerings are invaluable in the development of various consumer goods within the cannabis sector, ranging from wellness products to therapeutic medications. Furthermore, the company operates as a Contract Development and Manufacturing Organization (CDMO), serving to effectively bridge the gap between the cannabis industry and the broader consumer goods market. This branch of operations positions 22nd Century Group Inc at the forefront of the hemp and cannabis industries, capitalizing on the increasing demand for cannabinoid-based products. With a keen focus on research-driven innovation, 22nd Century Group Inc is propelling the development and commercialization of bioengineered plant technologies that have the potential to greatly impact human health and well-being. By drastically reducing the nicotine content in tobacco products, the company aims to mitigate the harm caused by smoking. Simultaneously, their involvement in the hemp and cannabis sector reflects the growing acceptance and recognition of the medicinal properties of these plants. Through their groundbreaking VLNC tobacco plants, research cigarettes, and hemp-derived cannabinoid ingredients, 22nd Century Group Inc is spearheading a transformation in the way nicotine and cannabidiol (CBD) are understood and utilized. By consistently pushing the boundaries of scientific advancements, the company stands firmly as a leader in the field of alkaloid plant technologies. Their dedication to health and wellness is poised to shape a brighter and healthier future for individuals worldwide. As 22nd Century Group Inc continues to innovate and expand its reach, its revenue streams are predominantly derived from the tobacco segment. However, it's important to recognize the long-term potential and growing significance of the hemp/cannabis segment. With the continuous evolution of regulations surrounding cannabis and the increasing demand for cannabinoid-based products, 22nd Century Group Inc is well-positioned to capitalize on this emerging market opportunity, further enhancing their revenue diversification and solidifying their position as a biotechnology leader.
Website: https://www.xxiicentury.com
Data updated: June 2, 2026
